Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Some studies have indicated the efficacy of quetiapine in the treatment of generalized anxiety disorder (GAD). OBJECTIVE: The purpose of this study was to systematically review the efficacy, acceptability, and tolerability of quetiapine in adult patients with GAD. METHODS: The SCOPUS, MEDLINE, CINAHL, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov databases were searched in April 2015. All randomized controlled trials (RCTs) of GAD were considered to be included in this meta-analysis. All RCTs of quetiapine in GAD patients providing endpoint outcomes relevant to severity of anxiety, response rate, remission rate, overall discontinuation rate, or discontinuation rate due to adverse events were included. The version reports from suitable clinical studies were explored, and the important data were extracted. Measurement for efficacy outcomes consisted of the mean-changed scores of the rating scales for anxiety, and response rate. RESULTS: A total of 2,248 randomized participants in three RCTs were included. The pooled mean-changed score of the quetiapine-treated group was greater than that of the placebo-treated group and comparable to selective serotonin reuptake inhibitors (SSRIs). Unfortunately, the response and the remission rates in only 50 and 150 mg/day of quetiapine-XR (extended-release) were better than those of the placebo. Their response and remission rates were comparable to SSRIs. The rates of pooled overall discontinuation and discontinuation due to adverse events of quetiapine-XR were greater than placebo. Only the overall discontinuation rate of quetiapine-XR at 50 and 150 mg/day and the discontinuation rate due to adverse events of quetiapine-XR at 50 mg/day were comparable to SSRIs. CONCLUSION: Based on this meta-analysis, quetiapine-XR is efficacious in the treatment of GAD in adult patients. Despite its low acceptability and tolerability, the use of 50-150 mg/day quetiapine-XR for adult GAD patients may be considered as an alternative treatment. Further well-defined studies should be conducted to warrant these outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing Risk of Bias in Included Studies
Higgins, J. P., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch8 · Cited by 3,396 · cited 2×
“48 In systematic reviews, either the fixed or the random effect model is applied for the synthesis of data.”
Analysing data and undertaking meta‐analyses
Deeks, J. J., Higgins, J. P., Altman, D. G., & on behalf of the Cochrane Statistical Methods Group (2019) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9781119536604.ch10 · Cited by 2,672
Analysing Data and Undertaking Meta‐Analyses
Deeks, J. J., Higgins, J. P., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch9 · Cited by 1,800
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Sterne, J. A., Egger, M., & Moher, D. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch10 · Cited by 651
Psychological treatment of generalized anxiety disorder: A meta-analysis
Cuijpers, P., Sijbrandij, M., Koole, S., Huibers, M., Berking, M., & Andersson, G. (2014) · Clinical Psychology Review · doi:10.1016/j.cpr.2014.01.002 · Cited by 527 · cited 13×
“As a rule, cognitive-behavioral therapy is effective in the treatment of GAD.(2) However, some GAD patients do not respond to cognitive-behavioral therapy because of severity and chronicity of GAD, presence of comorbidity, stressful events, lack of patient motivation, and resistance to therapy.”
InfluentialTyrer, P., & Baldwin, D. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69865-6 · Cited by 404 · cited 2×
“9%.(1,2) Since it is a disabling and chronic condition, it is a major burden for the individual, family, and health care services.”
Antidepressants and Sleep: A Qualitative Review of the Literature
Wilson, S., & Argyropoulos, S. (2005) · Drugs · doi:10.2165/00003495-200565070-00003 · Cited by 392
Sleep disturbance in generalized anxiety disorder and its treatment
Monti, J. M., & Monti, D. (2000) · Sleep Medicine Reviews · doi:10.1053/smrv.1999.0096 · Cited by 223 · cited 1×
“Although benzodiazepine, having faster onset of effect in GAD, 30 is effective in the treatment of insomnia in GAD patients, 27 use of this active drug may increase numerous risks, including drowsiness, falls, confusion, impaired memory and incoordination.”
Allgulander, C., Hackett, D., & Salinas, E. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.1.15 · Cited by 175
Bandelow, B., Chouinard, G., Bobes, J., Ahokas, A., Eggens, I., Liu, S., & Eriksson, H. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990423 · Cited by 142
(2010) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2010.02.010 · Cited by 80
Tolerability of Serotonin Norepinephrine Reuptake Inhibitor Antidepressants
Montgomery, S. A. (2008) · CNS Spectrums · doi:10.1017/s1092852900028297 · Cited by 65
Clinical experiences in conducting empirically supported treatments for generalized anxiety disorder
Szkodny, L. E., Newman, M. G., & Goldfried, M. R. (2014) · Behavior Therapy · doi:10.1016/j.beth.2013.09.009 · Cited by 47
Cited by
Penninx, B. W., Pine, D. S., Holmes, E. A., & Reif, A. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00359-7 · Cited by 740
Leichsenring, F., Steinert, C., Rabung, S., & Ioannidis, J. P. A. (2022) · World Psychiatry · doi:10.1002/wps.20941 · Cited by 485
Slee, A., Nazareth, I., Bondaronek, P., Liu, Y., Cheng, Z., & Freemantle, N. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31793-8 · Cited by 372
Pharmacotherapy for Anxiety Disorders: From First-Line Options to Treatment Resistance
Melaragno, A. J. (2021) · Focus · doi:10.1176/appi.focus.20200048 · Cited by 50
Manter, M. A., Birtwell, K. B., Bath, J., Friedman, N. D. B., Keary, C. J., Neumeyer, A. M., Palumbo, M. L., Thom, R. P., Stonestreet, E., Brooks, H., et al. (2025) · BMC Medicine · doi:10.1186/s12916-024-03814-0 · Cited by 51
“…can be increased by 25 mg every 5–7 days until an effective treatment response is reached or a maximum dose of 300 mg per day for chronic dosing is reached [107], though doses as high as 800 mg have been studied for the treatment of psychosis and some patients may be able to tolerate higher doses.”
Metadata
- Authors
- Maneeton, N., Maneeton, B., Woottiluk, P., Likhitsathian, S., Suttajit, S., Boonyanaruthee, V., & Srisurapanont, M.
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2016-01
- Volume
- 10
- Pages
- 259
- ISSN
- 1177-8881 (ISSN-L)
- OpenAlex
- W2234488921
- Cited by
- 77
- References
- 14
- FWCI
- 1.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.